Table 2. RSV-specific T cell responses during the first 6 weeks of disease.

Parameter (%) & Study visit	N	Median	IQR	P value wk 1 vs. wk 2	P value wk 1 vs. wk 6	P value wk 2 vs. wk 6
CD4+Perforin+
Week 1	25	3.5	2.5; 5.2	0.72	0.2	0.43
Week 2	24	4	2.9; 5.4
Week 6	20	4.5	5.5; 5.7
CD8+Perforin+
Week 1	25	5.1	3.2; 8.9	0.6	0.7	0.07
Week 2	24	4.8	3.2; 7.0
Week 6	20	5.4	4.3; 7.0
CD4+TNFα+
Week 1	25	1.5	0.4; 2.0	0.38	0.86	0.23
Week 2	24	1.6	0.9; 2.6
Week 6	20	1	0.8; 2.2
CD8+TNFα+
Week 1	25	1.6	1.1; 3.0	0.52	0.08	0.28
Week 2	24	1.3	0.9; 2.2
Week 6	20	1.2	0.8; 1.7
CD4+IL9+
Week 1	25	2.2	1.3; 2.7	0.4	0.1	0.5
Week 2	24	2.6	1.9; 3.0
Week 6	20	2.9	1.6; 4.0
CD8+IL9+
Week 1	25	2.4	1.9; 4.3	0.6	0.8	0.6
Week 2	24	3.1	1.8; 4.4
Week 6	20	3.6	2.1; 5.0
CD4+IL13+
Week 1	25	1.7	1.1; 2.0	0.7	0.8	0.8
Week 2	24	1.5	1.0; 2.3
Week 6	20	1.5	1.1; 2.7
CD8+IL13+
Week 1	25	2.1	1.3; 3.6	0.6	0.7	0.7
Week 2	24	2.2	1.3; 3.1
Week 6	20	2	1.2; 3.0
CD4+IL17+
Week 1	25	2	1.2; 2.8	0.3	0.8	0.4
Week 2	24	2	1.5; 3.0
Week 6	20	1.7	1.3; 2.7
CD8+IL17+
Week 1	25	2.7	0.6; 3.6	0.8	0.3	0.1
Week 2	24	2.3	1.5; 4.0
Week 6	20	2.2	1.7; 2.7
CD4+IL22+
Week 1	25	1.54	0.9; 2.0	0.3	0.6	0.03
Week 2	24	1.37	1.0; 2.4
Week 6	20	1.19	0.8; 1.7
CD8+ IL22+
Week 1	25	2.2	1.2; 3.1	0.27	0.01	0.01
Week 2	24	1.975	1.3; 2.5
Week 6	20	1.625	1.0; 2.2

Bold and italic underscore P values < 0.1 calculated by the Wilcoxon paired signed rank test.